MSD Pipeline

November 1, 2016

MSD Pipeline as of November 1, 2016

Phase 2	Phase 2	Phase 3	Phase 3	Phase 3	Phase 3
Asthma **MK-1029**	Diabetes Mellitus **MK-8521**	Alzheimer's Disease **verubecestat** **MK-8931**	Cancer **Bladder** **Breast** **Colorectal** **Esophageal** **Gastric** **Hepatocellular** **Head and Neck (EU)** **Hodgkin Lymphoma** **Multiple Myeloma** **Renal** **KEYTRUDA®** **MK-3475**	Diabetes Mellitus **ertugliflozin** **MK-8835** [1] **ertugliflozin+sitagliptin** **MK-8835A** [1] **ertugliflozin+metformin** **MK-8835B** [1]	HIV **doravirine** **MK-1439**
Cancer **PMBCL**[2] **Advanced solid tumors** **Nasopharyngeal** **Ovarian** **Prostate** **KEYTRUDA®** **MK-3475**	Hepatitis C **MK-3682/** **MK-5172(grazoprevir)** **/MK-8408(ruzasvir)** **MK-3682B**	Atherosclerosis **anacetrapib** **MK-0859**	CMV Prophylaxis in Transplant Patients **letermovir** **MK-8228**	Ebola Vaccine **V920**	HABP/VABP[3] bacterial pneumonia **ZERBAXA™** **MK-7625A**
Cancer **MK-2206** **MK-8628**	Pneumoconjugate Vaccine **V114**	Bacterial Infection **relebactam+imipenem/** **cilastatin** **MK-7655A**	Diabetes Mellitus **sitagliptin+ipragliflozin** **MK-0431J** [1] **(Japan)**	Herpes Zoster **inactivated VZV vaccine** **V212**	HABP/VABP[3] bacterial pneumonia **SIVEXTRO®** **MK-1986**
Cough, including cough w/ IPF[4] **MK-7264**		Heart Failure **Vericiguat** **MK-1242**[1]			

▶ Moved forward since last pipeline update.

1. Being developed in a collaboration.
2. Primary Mediastinal Large B-Cell Lymphoma
3. HABP - Hospital-acquired bacterial pneumonia/ VABP - ventilator-associated bacterial pneumonia
4. Idiopathic Pulmonary Fibrosis

MSD Be well

125 YEARS SINCE 1891

MSD Pipeline as of November 1, 2016

New Molecular Entities Under Review	**New Molecular Entities** Under Review	**New Molecular Entities** Approvals[1]	**New Molecular Entities** Approvals[1]	**New Molecular Entities** Approvals[1]	**New Molecular Entities** Approvals[1]
MK-8237 Allergy, House Dust Mite **(US)**[2]	**V419** Pediatric Hexavalent Combination Vaccine **(US)**[3]	**BRIDION®** **MK-8616** Neuromuscular Blockade Reversal **(US)**	**ZERBAXA®** **MK-7625A** Complicated intra-abdominal infections (cIAI) & complicated urinary tract infections (cUTI) **(US/EU)**	**GARDASIL®9** **V503** HPV Vaccine for Cancer Prevention **(US/EU)**	**KEYTRUDA®** **MK-3475** Melanoma **(EU)**
ZINPLAVA™ **MK-6072** *Clostridium difficile* Infection **(EU)**	**MK-1293** Diabetes Mellitus **(US/EU)**[4]	**MARIZEV®** **MK-3102** Diabetes Mellitus **(Japan)**	**ZEPATIER®** **MK-5172A** Hepatitis C **(US/EU)**	**VAXELIS™** **V419** Pediatric Hexavalent Combination Vaccine **(EU)**[3]	**ZINPLAVA™** **MK-6072** *Clostridium difficile* Infection **(US)**

Moved forward since last pipeline update.

1. Approvals obtained within the last 24 months.
2. MK-8237 was being developed as part of a North America partnership with ALK-Abelló (ALK). Merck has given ALK six months' notice that it is terminating the agreement and therefore this compound will be returned to ALK.
3. V419, the investigational pediatric hexavalent combination vaccine, DTaP5-IPV-Hib-HepB, is being developed in partnership with Sanofi Pasteur and if approved in the US, will be commercialized through that partnership. On November 2, 2015, the FDA issued a CRL with respect to V419. The companies are reviewing the CRL and plan to have further discussions with the FDA.
4. Being developed in a collaboration

Forward-Looking Statement

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in the presentation set forth below was current as of November 1, 2016. While this presentation remains on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after November 1, 2016.

The chart reflects the MSD's research pipeline as of November 1, 2016.

Candidates shown in Phase III include specific products. Candidates shown in Phase II include the most advanced compound with a specific mechanism in a given therapeutic area. Phase I candidates are not shown.